Navigation Links
Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
Date:10/22/2007

n from the FDA user fee, and FDA assistance in clinical trial design. Importantly, the Orphan Drug Act facilitates a close working relationship between regulatory agencies and companies aimed at accelerating the drug development and approval processes for treatment of rare diseases. For further information, please visit: http://www.fda.gov/orphan/oda.htm.

The European Medicines Agency is the European Union body responsible for coordinating the existing scientific resources put at its disposal by Member States for the evaluation, supervision and pharmacovigilance of medicinal products. The Agency provides the Member States and the institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, safety and efficacy of medicinal products for human or veterinary use referred to it in accordance with the provisions of EU legislation relating to medicinal products.

In 2001, the EMEA established the Committee for Orphan Medicinal Products (COMP), and charged it with reviewing designation applications from persons or companies who intend to develop medicines for rare diseases (so-called 'orphan drugs'). Orphan Medicinal drug products are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union at the time of the submission of the designation application. Orphan Medical Product Designation of SQ109 for the treatment of tuberculosis entitles Sequella to incentives such as protocol assistance (scientific advice during the product-development phase), 10-year marketing exclusivity, certain fee reductions or exemptions, and national incentives detailed in an inventory made available by the European Union, including the ability to apply for EU grants. For more information, visit:

SOURCE Sequella, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Isolation and Characterization of Anti-Viral Nucleoside Compounds from the Chinese Herb Taraxacum Mongolicum
2. TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds
3. UW compound counters Avian flu
4. Medical College receives $377K to study brain disease
5. Lucigen receives $750K grant to boost biofuel yields
6. Medical College receives $1.4M cancer grant
7. Wisconsin biotech firm receives $107K NIH grant
8. InvivoSciences receives NIH grant for heart technology
9. Medical College receives $11 million grant to study high blood pressure
10. Madison business receives $115,000 of new state biofuels funding
11. Superior receives funds for technical training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... HILDEN, Deutschland, May 26, 2015 ... ®   ermöglicht klinischen Laboren ... dazugehöriger Berichte; Vorstellung auf den Konferenzen ClinGen, ... N.V. (NASDAQ: QGEN ; Frankfurt Prime ... QIAGEN Clinical Insight ® (QCI™) bekannt. ...
(Date:5/26/2015)... CHENGDU, China , May 26, 2015 ... pharmaceutical company that specializes in the patented biopharmaceutical, modernized ... ingredients (API), announced that the Company,s Annual Meeting of ... was scheduled to be held at the Company,s office ... via conference call, at 9:00 AM (local time in ...
(Date:5/26/2015)... ANGELES , May 26, 2015 Pharmaco-Kinesis ... Board (NOCAB) recently convened at Shutters on the Beach ... review the development status of the Company,s innovative Metronomic ... designed to locally deliver chemotherapy over time to a ... dose delivery capacity and biofeedback system in real-time.  ...
(Date:5/26/2015)... 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... protocol for the company,s Phase IIb trial of ORMD-0801, ... Drug Administration (FDA). The submission was made under the ... The Phase IIb study of ORMD-0801 for type 2 ...
Breaking Biology Technology:QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3
... to the co-chairs of the state's Joint Legislative Audit ... for a performance review audit on data security practices in ... addressed to Senator Jim Sullivan , D-Wauwatosa, and ... security breaches, including the printing of more than 170,000 Social ...
... What is more important: diagnostics, therapeutics, or prognosis? While all ... history has addressed this question and also how recent events, ... diagnostics units, shed light on this fundamental issue. , ,It ... to not delve too deeply into its assumptions and to ...
... Wis. - Madison Development Corp ., a non-profit ... venture capital to two Dane County technology businesses. , ,MDC ... C5-6 Technologies, Inc., a biofuels spin off of Lucigen ... winner of the Governor's Business Plan Contest. , ,C5-6 Technologies, ...
Cached Biology Technology:A prognosis for GE and Abbott Diagnostics 2A prognosis for GE and Abbott Diagnostics 3A prognosis for GE and Abbott Diagnostics 4A prognosis for GE and Abbott Diagnostics 5A prognosis for GE and Abbott Diagnostics 6A prognosis for GE and Abbott Diagnostics 7
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/11/2015)... RYE, N.Y. , May 11, 2015 ... company, announced the start of a new Phase III ... effect of its novel formulation, CM-AT, on all children ... results of its FDA Phase III double blinded clinical ... who had low levels of the digestive enzyme chymotrypsin. ...
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... "where did life on Earth start?" now has a new ... correct, life would have originated between sheets of mica that ... so-called "life between the sheets" mica hypothesis was developed by ... funding from the National Science Foundation (NSF). This hypothesis was ...
... microtubules emanating from each of the spindle poles meet ... the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, ... of this overlap. In a study published today in ... anti-parallel microtubule overlaps in vitro, and identify two proteins ...
... group of scientists has identified a genetic variant that ... Jewish and other populations. The study, published by Cell ... of Human Genetics , associates a deletion on chromosome ... a psychiatric illness that affects 1% of the world ...
Cached Biology News:The secret of life may be as simple as what happens between the sheets -- mica sheets 2The secret of life may be as simple as what happens between the sheets -- mica sheets 3Constant overlap 2Large risk schizophrenia marker revealed 2
anti-achaete...
... Super-Dark, Super-Small! Capture high-resolution chemiluminescent ... Imaging System. High-sensitivity camera is cooled ... and wide dynamic range for high ... time. The light-tight cabinet provides optimum ...
... HEEBO (Human Exonic Evidence Based Oligonucleotide) Genome ... Oligonucleotide ) Genome Set contain a collection ... from constitutively expressed exons, allowing interrogation of ... leading researchers at Stanford University and UCSF, ...
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Biology Products: